GenKyoTex S.A.
http://www.genkyotex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenKyoTex S.A.
Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.
Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Updates With Olaparib, Niraparib And Ameluz
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Execs On The Move, November 2015
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- BT Pharma
- Genticel S.A.
- Gentle T Cell Vaccines